NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating whether Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ), or certain of its officers and directors, violated federal securities laws. If you purchased Frequency common stock and recently suffered a loss, you are encouraged to contact Scott+Scott attorney Joe Pettigrew at 844-818-6982 or firstname.lastname@example.org for more information.
Frequency is a clinical-stage biotechnology company. Its lead product candidate is FX-322, a potential treatment for hearing loss.
Our investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Frequency issued a press release on March 23, 2021, announcing topline data from its FX-322 Phase 2a study (FX-322-202). The Company admitted that “the interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo.”
On this news, Frequency’s stock price fell $28.30 per share – nearly 78% – to close at $7.99 per share on March 23, 2021.
What You Can Do
If you purchased Frequency common stock, and you wish to discuss this investigation, please contact attorney Joe Pettigrew at 844-818-6982, or at email@example.com, or visit the Frequency investigation page on our website at https://scott-scott.com/investigation/frequency-therapeutics-inc/.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.